<DOC>
	<DOC>NCT01009281</DOC>
	<brief_summary>This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.</brief_summary>
	<brief_title>An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients who participate and complete the core CAIN457A2202 study up to and including Visit 11 (end of study), may enter the extension study upon signing informed consent. Patients for whom continued treatment with AIN457 is not considered appropriate by the treating physician. Patients who were noncompliant or who demonstrated a mahor protocol violation in the core CAIN457A2202 study Patients who discontinued from the core CAIN457A2202 study before end of study. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Crohns</keyword>
	<keyword>Bowel disease</keyword>
	<keyword>digestive disorders</keyword>
	<keyword>auto immune</keyword>
	<keyword>diarrhea</keyword>
	<keyword>Inflammatory Bowel Disease (IBD)</keyword>
	<keyword>gastrointestinal diseases</keyword>
	<keyword>digestive system diseases</keyword>
	<keyword>Antibody</keyword>
	<keyword>IL 17</keyword>
	<keyword>anti IL-17</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>Crohn's Disease (Chron's, CD)</keyword>
</DOC>